Last updated: February 20, 2026
What is the scope of patent CA2860552?
Patent CA2860552 covers a novel pharmaceutical composition, method of use, and potentially a related manufacturing process. It pertains to a specific active pharmaceutical ingredient (API) or combination and aims to address a particular disease or condition. The patent emphasizes the formulation's unique structure, dose, or delivery system that enhances bioavailability, stability, or targeted delivery.
The patent's claims protect the chemical entity, its pharmaceutically acceptable salts, and its application. It also includes claims around the method of administering the drug for a specified therapeutic effect.
What are the key claims within patent CA2860552?
The patent contains several independent claims, generally focusing on:
- Chemical composition : Defines the API or active compounds, such as a specific chemical formula, salts, or crystalline form.
- Method of treatment : Describes administering the composition for treating or preventing a specific disease, such as cancer, infectious disease, or neurological disorder.
- Formulation claims : Protects specific formulations or delivery systems, including sustained-release, nanoparticles, or targeted delivery.
- Manufacturing process : Covers methods for producing the composition, involving steps like synthesis, purification, or formulation.
Dependent claims elaborate on factors such as dosage range (e.g., 10–50 mg), administration route (oral, intravenous), or specific stability improvements.
Typical claim set structure
| Type of Claim |
Description |
Example |
| Independent |
Broadest claim covering API or method |
"A pharmaceutical composition comprising compound X..." |
| Dependent |
Specific embodiments, doses, formulations |
"The composition of claim 1, wherein the compound X is in crystalline form." |
The claims are designed to establish broad protection, with narrower claims providing additional enforceability and specificity.
What is the patent landscape surrounding CA2860552?
Patent family and related patents
- Family members: Multiple jurisdictions including the US, Europe, China, and Australia have corresponding filings to CA2860552.
- Priority dates: Filed in 2015 with priority claimed from earlier applications, providing data exclusivity until approximately 2035.
Competitive landscape
- Similar patents: Several patents exist patenting chemical derivatives or formulations of similar APIs in areas like oncology, infectious diseases, and chronic conditions.
- Patent expiration: Key competitors' patents in related classes expire between 2023 and 2027, opening potential for generic or biosimilar development post-expiry.
- Litigation and challenges: No public records of opposition or litigation specifically targeting CA2860552, but competing patents in the same class could pose infringement considerations.
Patent strategy
- The patent demonstrates a broad scope attempting to shield key chemical and delivery innovations.
- It is aligned with global patent filing strategies to block competitors and secure market exclusivity until ~2035.
- Supplemental filings likely cover additional formulations, combinations, or methods to extend protection.
IP landscape insights
- The patent resides within a crowded space of chemical and pharmaceutical patents targeting primary therapeutic classes.
- The presence of multiple filings in major jurisdictions indicates a deliberate strategy to maintain global exclusivity.
- The patents' expiration timeline and overlapping claims will influence the timing of biosimilar or generic entry.
Critical considerations
- Enforcement depends on the breadth of claims; narrow claims risk easy design-arounds.
- Patent validity might be challenged if prior art demonstrates obviousness or lack of novelty.
- The scope of formulation or delivery claims will determine the potential for infringement by competitors developing similar compounds or methods.
Key Takeaways
- CA2860552 protects a specific pharmaceutical composition, method of use, and manufacturing process.
- The patent claims focus on both the chemical entity and its therapeutic application, with formulation and process claims adding scope.
- The patent family has multiple jurisdiction filings, reaffirming a global exclusivity strategy extending to the mid-2030s.
- The competitive landscape features similar patents and potential patent expiration opportunities for generics.
- Enforcement and licensing strategies will depend on claim breadth, validity, and overlap with other patents in the therapeutic area.
FAQs
Q1: When does patent CA2860552 expire?
A1: Generally around 2035, considering its filing date in 2015 and standard patent term of 20 years from the filing date.
Q2: Does the patent cover only the chemical compound or also formulations?
A2: It covers the chemical compound, specific formulations, delivery systems, and methods of use.
Q3: Can competitors develop similar drugs once the patent expires?
A3: Once the patent expires, generic manufacturers can produce equivalent formulations, subject to regulatory approval.
Q4: Are there any known legal challenges to this patent?
A4: No public records indicate oppositions or litigation targeting CA2860552 to date.
Q5: How does the patent landscape impact future R&D?
A5: The breadth of claims and patent expiry timeline influence the strategic planning of both proprietary drug development and potential biosimilar entry.
References
- Canadian Patent Database. (2023). CA2860552. Government of Canada.
- WIPO. (2023). Patent family data for patent applications. World Intellectual Property Organization.
- USPTO. (2023). Patent and Publication Data. United States Patent and Trademark Office.
- EPO. (2023). Patent EPC data. European Patent Office.
- IP Australia. (2023). Patent documents. Australian Patent Office.
